SynthesisMalaria journal2026
Evaluating the safety, pharmacokinetics, and antiparasitic activity of DSM265, a novel antimalarial plasmodium dihydroorotate dehydrogenase inhibitor: a systematic review and meta-analysis of early clinical trials.
Synthesis in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe growing resistance to current antimalarial drugs has stalled the eradication of malaria in endemic countries. DSM265 has recently been studied in phase I and II clinical trials.
aimThis meta-analysis aims to evaluate the safety, pharmacokinetics (PK), and antiparasitic activity of DSM265 based on available early-phase clinical trials.
methodsThis systematic review (PROSPERO: CRD42024499167) was conducted to identify any relevant clinical trials reporting DSM265 safety and PK data. Five databases were searched, i.e., PubMed, Cochrane CENTRAL, EBSCOhost, Clinicaltrials.gov, and ScienceDirect. Eligible clinical trials on DSM265 that reported safety outcomes and PK parameters were included. The risk of bias was assessed by Cochrane's Collaboration tool. Meta-analysis was conducted to present the pooled adverse events (AEs) and summary estimates for PK parameters, including maximum drug concentration (C
resultsSeven trials were eligible for systematic review. Overall, DSM265 was associated with increased risks of AEs (relative risk [RR] [95% CI] = 1.46 [1.15, 1.84]); subgroup analysis showed significant risks only among the low-dose (25-250 mg) (RR [95% CI] = 1.86 CI [1.36, 2.54]) and high-dose (600-1200 mg) (RR [95% CI] = 1.67 CI [1.03, 2.72]) subgroups. When given as oral suspension at 400 mg dose, DSM265 achieved C
conclusionIn this meta-analysis, DSM265 demonstrated a favorable safety profile after a single 400 mg dose. While preclinical signals of teratogenicity and testicular toxicity have halted further development, these effects were not reported in the included clinical trials. Substantial variability in PK parameters was noted, driven primarily by administered doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.